• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Concise drug review: azacitidine and decitabine.简明药物评论：阿扎胞苷和地西他滨。
Oncologist. 2013;18(5):619-24. doi: 10.1634/theoncologist.2012-0465. Epub 2013 May 13.
2
Decitabine dosage in myelodysplastic syndromes.骨髓增生异常综合征中的地西他滨剂量
Blood. 2007 Aug 1;110(3):1082-3; author reply 1083. doi: 10.1182/blood-2007-03-080903.
3
The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.口服低甲基化药物在急性髓细胞白血病和骨髓增生异常综合征中的获批之路。
Future Oncol. 2021 Jul;17(20):2563-2571. doi: 10.2217/fon-2020-1318. Epub 2021 Mar 26.
4
Clinical update on hypomethylating agents.低甲基化剂的临床最新进展。
Int J Hematol. 2019 Aug;110(2):161-169. doi: 10.1007/s12185-019-02651-9. Epub 2019 Apr 24.
5
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.低剂量地西他滨三种给药方案用于高危骨髓增生异常综合征和慢性粒单核细胞白血病的随机研究结果
Blood. 2007 Jan 1;109(1):52-7. doi: 10.1182/blood-2006-05-021162. Epub 2006 Aug 1.
6
The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.口服低甲基化剂在急性髓系白血病和骨髓增生异常综合征中的研发和临床应用：全口服治疗时代的曙光。
Expert Rev Anticancer Ther. 2021 Sep;21(9):989-1002. doi: 10.1080/14737140.2021.1918002. Epub 2021 Apr 28.
7
Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.地西他滨治疗骨髓增生异常综合征和慢性粒单核细胞白血病的阿根廷/韩国多机构临床经验。
Leuk Lymphoma. 2010 Dec;51(12):2250-7. doi: 10.3109/10428194.2010.524324. Epub 2010 Oct 7.
8
Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.口服低甲基化药物治疗骨髓增生异常综合征/肿瘤和急性髓系白血病的临床活性、药代动力学和药效学：多学科综述。
J Oncol Pharm Pract. 2024 Jun;30(4):721-736. doi: 10.1177/10781552241238979. Epub 2024 Mar 21.
9
Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.地西他滨与阿扎胞苷治疗骨髓增生异常综合征的比较：一项纳入1392名参与者的荟萃分析。
Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):22-8. doi: 10.1016/j.clml.2014.04.010. Epub 2014 Jun 12.
10
[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].5天阿扎胞苷治疗伴有复杂核型异常的骨髓增生异常综合征及急性髓系白血病
Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):542-3. doi: 10.3760/cma.j.issn.0253-2727.2013.06.019.

引用本文的文献

1
Disrupting the epigenetic alliance: structural insights and therapeutic strategies targeting DNMT1-UHRF1.破坏表观遗传联盟：靶向DNMT1-UHRF1的结构见解与治疗策略
Funct Integr Genomics. 2025 Sep 17;25(1):194. doi: 10.1007/s10142-025-01708-9.
2
Genome-wide DNA methylation analysis identifies kidney epigenetic dysregulation in a cystinosis mouse model.全基因组DNA甲基化分析揭示了胱氨酸病小鼠模型中的肾脏表观遗传失调。
Front Cell Dev Biol. 2025 Aug 21;13:1638123. doi: 10.3389/fcell.2025.1638123. eCollection 2025.
3
Mechanism of action of decitabine in treating acute lymphoblastic leukemia.地西他滨治疗急性淋巴细胞白血病的作用机制。
Front Med (Lausanne). 2025 Jul 30;12:1614592. doi: 10.3389/fmed.2025.1614592. eCollection 2025.
4
DNA methylation in chronic kidney disease.慢性肾脏病中的DNA甲基化
BMC Nephrol. 2025 Aug 13;26(1):455. doi: 10.1186/s12882-024-03916-0.
5
The role of DNA methylation and demethylation in bladder cancer: a focus on therapeutic strategies.DNA甲基化与去甲基化在膀胱癌中的作用：聚焦治疗策略
Front Oncol. 2025 Jun 26;15:1567242. doi: 10.3389/fonc.2025.1567242. eCollection 2025.
6
Wnt/Ca signaling: Dichotomous roles in regulating tumor progress (Review).Wnt/Ca信号传导：在调节肿瘤进展中的双重作用（综述）
Oncol Lett. 2025 Jun 18;30(2):399. doi: 10.3892/ol.2025.15145. eCollection 2025 Aug.
7
Nanotechnology-driven Epigenetic Cancer Therapy: Precision Delivery and Sustained Release of DNA Methylation Modulators.纳米技术驱动的表观遗传癌症治疗：DNA甲基化调节剂的精准递送与缓释
Yale J Biol Med. 2025 Jun 30;98(2):227-235. doi: 10.59249/GVNM8843. eCollection 2025 Jun.
8
Uncovering a Novel Role of ROR1 in the Epigenetic Regulation of Tumor Suppressor Gene CREB3L1 in Triple-Negative Breast Cancer Cells.揭示ROR1在三阴性乳腺癌细胞中肿瘤抑制基因CREB3L1表观遗传调控中的新作用。
Biomolecules. 2025 May 16;15(5):734. doi: 10.3390/biom15050734.
9
Ubiquitin proteasome system (UPS): a crucial determinant of the epigenetic landscape in cancer.泛素蛋白酶体系统（UPS）：癌症表观遗传格局的关键决定因素。
Epigenomics. 2025 Jun;17(9):625-644. doi: 10.1080/17501911.2025.2501524. Epub 2025 May 8.
10
Recent advances on gene-related DNA methylation in cancer diagnosis, prognosis, and treatment: a clinical perspective.癌症诊断、预后及治疗中基因相关DNA甲基化的最新进展：临床视角
Clin Epigenetics. 2025 May 5;17(1):76. doi: 10.1186/s13148-025-01884-2.

本文引用的文献

1
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.表观遗传学治疗与强化化疗在新诊断的老年急性髓系白血病患者中的生存相似。
Blood. 2012 Dec 6;120(24):4840-5. doi: 10.1182/blood-2012-06-436055. Epub 2012 Oct 15.
2
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.来那度胺和阿扎胞苷联合治疗高危骨髓增生异常综合征患者的 2 期研究。
Blood. 2012 Dec 13;120(25):4945-51. doi: 10.1182/blood-2012-06-434639. Epub 2012 Aug 22.
3
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.多中心、随机、开放标签、III 期临床试验，比较地西他滨与患者选择的支持治疗或低剂量阿糖胞苷治疗新诊断的老年急性髓系白血病，患者选择方案由医生提供建议。
J Clin Oncol. 2012 Jul 20;30(21):2670-7. doi: 10.1200/JCO.2011.38.9429. Epub 2012 Jun 11.
4
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.阿扎胞苷治疗失败后骨髓增生异常综合征继发急性髓系白血病的预后
Br J Haematol. 2012 Jun;157(6):764-6. doi: 10.1111/j.1365-2141.2012.09076.x. Epub 2012 Mar 6.
5
Optimizing hypomethylating agents in myelodysplastic syndromes.优化骨髓增生异常综合征中的去甲基化剂。
Curr Opin Hematol. 2012 Mar;19(2):65-70. doi: 10.1097/MOH.0b013e32834ff58a.
6
Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents.预测接受去甲基化药物治疗的高危骨髓增生异常综合征患者的预后。
Leuk Lymphoma. 2012 May;53(5):760-2. doi: 10.3109/10428194.2011.651618. Epub 2012 Jan 31.
7
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.将法国预后评分应用于接受5-氮杂胞苷治疗的国际预后评分系统中危-2或高危骨髓增生异常综合征患者，能够预测总生存期和缓解率。
Leuk Lymphoma. 2012 May;53(5):985-6. doi: 10.3109/10428194.2011.643408. Epub 2012 Jan 11.
8
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.在荷兰阿扎胞苷同情用药计划中，第一个阿扎胞苷周期后血小板倍增是骨髓增生异常综合征（MDS）、慢性粒单核细胞白血病（CMML）和急性髓系白血病（AML）患者反应的有希望的预测指标。
Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.
9
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.阿扎胞苷治疗失败后高危骨髓增生异常综合征的结局。
J Clin Oncol. 2011 Aug 20;29(24):3322-7. doi: 10.1200/JCO.2011.35.8135. Epub 2011 Jul 25.
10
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.持续的阿扎胞苷治疗超过首次缓解时间可改善高危骨髓增生异常综合征患者的缓解质量。
Cancer. 2011 Jun 15;117(12):2697-702. doi: 10.1002/cncr.25774. Epub 2011 Jan 10.

简明药物评论：阿扎胞苷和地西他滨。

Concise drug review: azacitidine and decitabine.

机构信息

Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands.

出版信息

Oncologist. 2013;18(5):619-24. doi: 10.1634/theoncologist.2012-0465. Epub 2013 May 13.

DOI:10.1634/theoncologist.2012-0465
PMID:23671007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3662854/
Abstract

The introduction of the hypomethylating agents azacitidine and decitabine has been a major advancement in the treatment of patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia who are ineligible for more intensive treatments. This concise drug review summarizes the current state of treatment with azacitidine and decitabine.

摘要

低甲基化药物阿扎胞苷和地西他滨的引入是治疗不适合更强化疗的高危骨髓增生异常综合征、慢性粒单核细胞白血病和急性髓系白血病患者的重大进展。本简明药物综述总结了阿扎胞苷和地西他滨的治疗现状。